Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4

Kaori Miyazaki, Yoichiro Abe, Hiroko Iwanari, Yota Suzuki, Takahiro Kikuchi, Takashi Ito, Jungo Kato, Osamu Kusano-Arai, Toshiyuki Takahashi, Shuhei Nishiyama, Hiroko Ikeshima-Kataoka, Shoji Tsuji, Takeshi Arimitsu, Yasuhiro Kato, Toshiko Sakihama, Yoshiaki Toyama, Kazuo Fujihara, Takao Hamakubo, Masato Yasui

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)

Abstract

Neuromyelitis optica is a demyelinating disease characterized by a disease-specific autoantibody designated as NMO-IgG that specifically recognizes aquaporin-4, and the binding of NMO-IgG to AQP4 causes the progress of the disease. Prevention of the binding of NMO-IgG, therefore, may alleviate the disease. Here we have developed monoclonal antibodies against AQP4 with a baculovirus display system in order to obtain high affinity monoclonal antibodies against the extracellular domains of AQP4. Our monoclonal antibodies can block the binding of NMO-IgG in spite of their heterogeneity. Taken together, we propose that our monoclonal antibodies can be applied in clinical therapy for NMO patients.

Original languageEnglish
Pages (from-to)107-116
Number of pages10
JournalJournal of Neuroimmunology
Volume260
Issue number1-2
DOIs
Publication statusPublished - 2013

Keywords

  • Aquaporin-4
  • Monoclonal antibody
  • NMO-IgG
  • Nueromyelitis optica

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4'. Together they form a unique fingerprint.

Cite this